---
title: 'Senior Manager, Statistical Programming at IMVT Corporation'
canonical: 'https://feeny.ai/job/senior-manager-statistical-programming-imvt-corporation-remote-6q5z9h7nwxvn'
type: 'job'
last_seen: '2026-10-16'
---

# Senior Manager, Statistical Programming at IMVT Corporation

- **Company:** IMVT Corporation
- **Location:** Remote
- **Compensation:** $175k–$195k
- **Work type:** remote
- **Posted:** 2026-10-15
- **Last confirmed live:** 2026-10-16
- **Apply:** https://job-boards.greenhouse.io/imvtcorporation/jobs/6225302004

## Job description

Immunovant, Inc. is a clinical-stage biopharmaceutical company dedicated to enabling normal lives for people with autoimmune diseases. As trailblazers in FcRn inhibitor technology, the Company is boldly developing innovative therapies for a range of debilitating autoimmune diseases with significant unmet patient needs.

The Role:

Immunovant is seeking a Senior Manager, Statistical Programming. This position is responsible for performing the programming and statistical analyses necessary to analyze the results of clinical trials and related research activities. This position also contributes to the interpretation of the results of these analyses and provides statistical input for the reporting of the results. This person will also validate and cross-check the relevance and accuracy of the statistical programs and the resulting Tables, Listings and Graphs (TLGs) developed by external Clinical Research Organizations (CROs) and participate in the development and maintenance of SAS macro library and safety database.

Key Responsibilities:

- Interacts with Contract Research Organizations (CROs) involved in data management/analysis activities to ensure that their statistical analyses and resulting outputs are accurate and consistent with the contractually agreed upon deliverables. Works with vendor staff to characterize and resolve issues related to data analysis.
- Produces timely statistical analyses of clinical and related data per protocols and SAPs. Develops statistical programs and produces programmed outputs used to create integrated scientific reports for clinical trial results.
- Participates in the development and maintenance of internal SAS macro library and safety database.
- Provides statistical input for Statistical Analysis Plans (SAPs), publication activities, scientific presentations and promotional material.
- Participates in the review of Case Report Forms (CRFs), CRF annotations, SAPs, and TLG shells and TLGs.
- Participates in study team meetings as a representative of the statistical programming function. Communicates statistical issues and acts as a statistical/programming resource to the development teams.
- Participates in the assessment, selection and evaluation of CROs.
- Creates and reviews derived dataset specifications and the related analysis datasets.
- Develops training guidelines related to statistical programming.

Requirements:

- Master’s degree in a quantitative sciences discipline (e.g., Statistics, Mathematics, Computer Science) and a minimum of 7 years in statistics or statistical programming in a biotech/pharmaceutical or CRO environment.
- Bachelor’s degree in a quantitative sciences discipline (e.g., Statistics, Mathematics, Computer Science) and a minimum of 10 years in statistics or statistical programming in a biotech/pharmaceutical or CRO environment.
- Excellent SAS programming skills (e.g., Base SAS, SAS/Stat, SAS/Graph, SAS macros, ODS) and a good understanding of database systems.
- Experience leading programming activities involving CDISC SDTM, ADaM, and eSubmission (e.g., define.xml, ADRG/SDRG).
- Applied knowledge of clinical data analysis and reporting process as it relates to drug development.
- Excellent interpersonal and communication skills.
- Good organizational skills with the ability to adapt and adjust to changing priorities.
- Experience working with CROs.
- NDA/MAA submission experience.

Work Environment:

- The position will be remote and headquarters based in Durham, NC.
- Dynamic, interactive, fast-paced, and entrepreneurial environment.
- Domestic or international travel may be required (~10%).

Salary range for posting $175,000—$195,000 USD

Compensation is based on a number of factors, including market location, and may vary depending on job-related knowledge, skills, and experience. Equity and other forms of compensation may be provided as part of a total compensation package, in addition to a full range of medical, dental, vision, 401k, and other benefits, including unlimited paid time off and parental leave.

## About IMVT Corporation

## Company Overview
- **One-liner**: A clinical-stage immunology company developing innovative anti-FcRn therapies to enable normal lives for people with autoimmune diseases.
- **Entity Type**: Public (Nasdaq: IMVT)
- **Headquarters**: Durham, North Carolina, United States
- **Founded**: Not publicly available
- **Founders**: Not publicly available

## Core Business
- **Primary industry**: Biotechnology / Autoimmune disease therapeutics
- **Target customers**: Patients with IgG-mediated autoimmune diseases; healthcare providers; payers (B2B/B2C mix via prescription drugs)
- **Mission or purpose statement**: “Dedicated to enabling normal lives for people with autoimmune diseases” [immunovant.com](https://www.immunovant.com/)

## Products & Services
- **[IMVT-1402 (imeroprubart)]**: A novel, fully human monoclonal antibody that targets FcRn to reduce pathogenic IgG autoantibodies. Designed as a subcutaneous injection with a simple autoinjector (YpsoMate®). In clinical development for six indications: Graves’ disease (GD), difficult-to-treat rheumatoid arthritis (D2T RA), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP), Sjögren’s disease (SjD), and cutaneous lupus erythematosus (CLE). [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)
- **[Batoclimab (first-generation anti-FcRn)]**: Development discontinued across all indications after Phase 3 TED trials did not meet primary endpoints; learnings inform IMVT-1402 program. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Market Standing
- **Valuation/Market Cap**: Not disclosed in available sources (publicly traded on Nasdaq; refer to real-time market data).
- **Key Metric**: Clinical-stage company with no approved products or revenue; total funding and operating expenses are detailed in SEC filings but not summarized here.
- **Notable Investors/Partners**: HanAll Biopharma (collaboration on anti-FcRn antibodies); Ypsomed AG (auto-injector YpsoMate®). [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)
- **Growth Signals**: Six ongoing clinical programs (including potentially registrational trials); deep IgG reductions (~80% with weekly 600 mg IMVT-1402) suggesting best-in-class potential; Phase 1 safety data showing no/minimal albumin reduction or LDL cholesterol increases. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Competitive Advantages
- **Potential best-in-class efficacy**: IMVT-1402 achieves deeper IgG reductions than competitor anti-FcRn antibodies, correlating with improved clinical outcomes.
- **Favorable safety profile**: No or minimal off-target effects on albumin and LDL cholesterol, unlike some FcRn inhibitors.
- **Convenient administration**: Self-administered subcutaneous autoinjector (YpsoMate®) expected at launch, improving patient adherence.
- **Broad pipeline**: Six indications in development across endocrinology, rheumatology, neurology, and dermatology, with potential for more.

## Strategic Focus
- Execute pivotal trials for IMVT-1402 in GD, D2T RA, MG, CIDP, SjD, and CLE.
- Leverage learnings from batoclimab program to accelerate IMVT-1402 development.
- Plan to assess new indications for IMVT-1402 beyond the initial six.
- Continue to build commercial capabilities for eventual launch. [10-K (2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Why Work Here
- **Culture**: Emphasizes “Hire and Retain Only the Very Best,” “One Team, Shared Success,” “Ownership Mentality,” and “Patients Are Waiting” – a mission-driven, high-performance environment. [About Us](https://www.immunovant.com/about-us)
- **Remote/Hybrid Policy**: Job listings show a mix of remote and hybrid roles (e.g., “Remote” for many positions, “Hybrid - NYC” for commercial roles). [Careers](https://www.immunovant.com/join-us/explore-careers)
- **Notable Perks**: Merit-based recognition, focus on impact and results, creative problem-solving encouraged. [About Us](https://www.immunovant.com/about-us)
- **Engineering/Science Culture**: Clinical-stage biotech with cutting-edge FcRn technology; opportunities in clinical development, biometrics, quality assurance, and commercial roles. [Careers](https://www.immunovant.com/join-us/explore-careers)

## Sources
1. [Immunovant Corporate Website](https://www.immunovant.com/)
2. [About Us – Values and Culture](https://www.immunovant.com/about-us)
3. [Company Information – Investor Relations](https://www.immunovant.com/investors/company-information)
4. [Explore Careers – Job Listings](https://www.immunovant.com/join-us/explore-careers)
5. [10-K SEC Filing (May 20, 2026)](https://www.immunovant.com/investors/sec-filings/all-sec-filings/content/0001764013-26-000064/0001764013-26-000064.pdf)

## Other roles at IMVT Corporation

- [Director, Financial Planning & Analysis](https://feeny.ai/job/director-financial-planning-analysis-imvt-corporation-remote-2xtk0zhd4zbr)
- [Executive Assistant](https://feeny.ai/job/executive-assistant-imvt-corporation-new-york-m7dv0wr8rkjs) — New York, NY
- [Senior Director, Biostatistics](https://feeny.ai/job/senior-director-biostatistics-imvt-corporation-remote-swdw529e6zxr)
- [Director, Medical Science Liaison (MSL)](https://feeny.ai/job/director-medical-science-liaison-msl-imvt-corporation-southeast-cnykwbftkpjw) — Southeast, United States
- [Director, Marketing](https://feeny.ai/job/director-marketing-imvt-corporation-remote-4t6kt28mgdh0)
- [Senior Manager, Statistical Programming](https://feeny.ai/job/senior-manager-statistical-programming-immunome-inc-bothell-wp8jzns2hctg) — Bothell, WA